Candel Therapeutics, Inc. (CADL)
6.20
-2.19
(-26.10%)
USD |
NASDAQ |
Nov 13, 16:00
6.05
-0.15
(-2.42%)
After-Hours: 19:59
Candel Therapeutics Debt to Equity Ratio : 0.3782 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.3782 |
| June 30, 2026 | 0.3926 |
| March 31, 2026 | 0.357 |
| December 31, 2025 | 0.9444 |
| September 30, 2025 | 0.0899 |
| June 30, 2025 | 0.0925 |
| March 31, 2025 | 0.1461 |
| December 31, 2024 | 0.2031 |
| September 30, 2024 | -1.050 |
| June 30, 2024 | -1.861 |
| March 31, 2024 | 3.526 |
| December 31, 2023 | 1.786 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.9891 |
| June 30, 2023 | 0.7403 |
| March 31, 2023 | 0.5747 |
| December 31, 2022 | 0.4778 |
| September 30, 2022 | 0.4375 |
| June 30, 2022 | 0.3795 |
| March 31, 2022 | 0.3575 |
| December 31, 2021 | 0.0087 |
| September 30, 2021 | 0.0086 |
| June 30, 2021 | 0.0885 |
| March 31, 2021 | 0.0448 |
| December 31, 2020 | 0.0371 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Oragenics, Inc. | 0.363 |
| Arcturus Therapeutics Holdings, Inc. | 0.1296 |
| ACADIA Pharmaceuticals, Inc. | 0.0518 |
| Alnylam Pharmaceuticals, Inc. | 0.8316 |
| Anika Therapeutics, Inc. | 0.1901 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 211.11M |
| Total Liabilities (Quarterly) | 79.52M |
| Shareholders Equity (Quarterly) | 131.59M |
| Current Ratio | 7.571 |
| Net Debt Paydown Yield | -1.01% |